Dimensional Fund Advisors LP Sells 169,888 Shares of Alector, Inc. (NASDAQ:ALEC)

Dimensional Fund Advisors LP trimmed its holdings in shares of Alector, Inc. (NASDAQ:ALEC) by 20.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 676,076 shares of the company’s stock after selling 169,888 shares during the period. Dimensional Fund Advisors LP owned about 0.70% of Alector worth $3,069,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of ALEC. Allspring Global Investments Holdings LLC purchased a new position in Alector in the 1st quarter worth approximately $40,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Alector by 89.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 18,403 shares of the company’s stock worth $111,000 after purchasing an additional 8,670 shares during the period. Swiss National Bank increased its holdings in Alector by 6.5% during the 1st quarter. Swiss National Bank now owns 131,900 shares of the company’s stock valued at $794,000 after purchasing an additional 8,000 shares during the period. Susquehanna Fundamental Investments LLC bought a new position in Alector during the 1st quarter valued at approximately $760,000. Finally, Russell Investments Group Ltd. grew its position in shares of Alector by 9.9% in the 1st quarter. Russell Investments Group Ltd. now owns 78,348 shares of the company’s stock worth $472,000 after buying an additional 7,066 shares during the last quarter. 85.83% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $35.00 price objective on shares of Alector in a research report on Thursday, June 20th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alector in a report on Tuesday, September 17th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $17.75.

Alector Price Performance

Shares of NASDAQ:ALEC opened at $4.55 on Friday. The company has a market capitalization of $438.55 million, a PE ratio of -3.30 and a beta of 0.68. The business has a fifty day moving average price of $5.12 and a 200-day moving average price of $5.23. Alector, Inc. has a 1-year low of $3.66 and a 1-year high of $8.90.

Alector (NASDAQ:ALEC) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.09. Alector had a negative net margin of 290.66% and a negative return on equity of 102.63%. The firm had revenue of $15.08 million for the quarter, compared to analysts’ expectations of $16.04 million. During the same quarter in the prior year, the company posted $0.02 earnings per share. On average, sell-side analysts anticipate that Alector, Inc. will post -1.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Sara Kenkare-Mitra sold 13,926 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $4.88, for a total transaction of $67,958.88. Following the sale, the insider now directly owns 291,715 shares of the company’s stock, valued at $1,423,569.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, insider Sara Kenkare-Mitra sold 13,926 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total value of $67,958.88. Following the sale, the insider now owns 291,715 shares in the company, valued at approximately $1,423,569.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Arnon Rosenthal sold 26,499 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total transaction of $129,315.12. Following the sale, the chief executive officer now owns 1,948,746 shares of the company’s stock, valued at approximately $9,509,880.48. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 58,222 shares of company stock valued at $286,013. Corporate insiders own 9.10% of the company’s stock.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.